Quarterly ResultMay 14, 2026, 05:33 PM
Valion Bio Q1 Net Loss $6.2M; Going Concern Doubt, Nasdaq Non-Compliance
AI Summary
Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) reported a net loss of $6.2 million for Q1 2026, significantly wider than the $1.5 million loss in Q1 2025. The company's cash and cash equivalents decreased to $7.2 million, and it used $5.0 million in cash from operations, raising substantial doubt about its ability to continue as a going concern. Additionally, Valion Bio received a Nasdaq notification for non-compliance with the minimum bid price requirement. The company also completed the wind-down of its ClearUP business.
Key Highlights
- Q1 2026 net loss widened to $6.2 million from $1.5 million in Q1 2025.
- Cash and cash equivalents decreased to $7.2 million as of March 31, 2026, from $12.6 million at year-end 2025.
- Used $5.0 million in cash from operating activities in Q1 2026, up from $0.9 million in Q1 2025.
- Accumulated deficit reached $59.0 million as of March 31, 2026.
- Received Nasdaq notification on March 19, 2026, for non-compliance with the $1.00 minimum bid price rule.
- Research and development expenses increased to $1.9 million in Q1 2026 from $0.3 million in Q1 2025.
- Selling, general and administrative expenses rose to $3.8 million in Q1 2026 from $1.0 million in Q1 2025.
- Company changed its name from Tivic Health Systems, Inc. to Valion Bio, Inc. in April 2026.